Amphastar Pharmaceuticals Inc 's Income per employee fell in the first quarter 2026 on a trailing twelve month basis to $ 40,096, but the productivity of Amphastar Pharmaceuticals Inc 's 1,976 employees remained above the company average.
The Healthcare sector has seen employees of 63 other companies achieving higher income per employee. While Amphastar Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 982 to 1470.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AMPH Net Income per Employee	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Net Income Change	-74.61 %	-35.65 %	-57.09 %	-18.23 %	-41.44 %
Net Income per Employee (TTM) $	40,096	49,643	56,492	68,172	71,674
AMPH's Total Ranking	# 1470	# 982	# 1203	# 990	# 963
Seq. Net Income Change	-73.72 %	40.8 %	-44.09 %	22.72 %	-33.4 %

AMPH Company Profile >> Back to AMPH Efficiency Comparisons >> Compare AMPH Net Income per Employee to its Competitors

AMPH Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 64
Healthcare Sector	# 131
Overall Market	# 1470

Net Income per Employee Statistics
High	Average	Low
$ 85,524	$ 29,196	$ -5,218
(Sep 30 2024)		(Jun 30 2018)

Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Mar 31 2026	Number of Employees Mar 31 2026
Edwards Lifesciences Corporation	68,356.25	$ 1,093.700 Million	16,000
Alpha Pro Tech Ltd	68,308.94	$ 8.402 Million	123
Protalix Biotherapeutics inc	67,840.71	$ 15.332 Million	226
Corcept Therapeutics Inc	63,946.58	$ 46.681 Million	730
Abbvie Inc	63,877.19	$ 3,641.000 Million	57,000
Embecta Corp	60,486.49	$ 111.900 Million	1,850
Boston Scientific Corporation	60,322.03	$ 3,559.000 Million	59,000
Stryker Corp	59,589.29	$ 3,337.000 Million	56,000
Utah Medical Products Inc	59,278.69	$ 10.848 Million	183
Pro dex Inc	58,262.14	$ 12.002 Million	206
Waters Corporation	56,866.84	$ 449.248 Million	7,900
Insulet Corporation	56,074.07	$ 302.800 Million	5,400
Msa Safety Inc	54,827.92	$ 290.588 Million	5,300
Abbott Laboratories	54,573.91	$ 6,276.000 Million	115,000
Vericel Corporation	53,924.62	$ 21.462 Million	398
Mettler toledo International Inc	52,714.46	$ 875.060 Million	16,600
Profound Medical Corp	52,123.46	$ 8.444 Million	162
Electromed Inc	51,289.34	$ 10.104 Million	197
Medtronic Plc	50,915.79	$ 4,837.000 Million	95,000
West Pharmaceutical Services Inc	50,250.00	$ 542.700 Million	10,800
Sbc Medical Group Holdings Incorporated	47,372.07	$ 40.882 Million	863
3m Company	46,264.46	$ 2,799.000 Million	60,500
Teva Pharmaceutical Industries Limited	46,156.11	$ 1,567.000 Million	33,950
Arcutis Biotherapeutics Inc	46,090.40	$ 16.316 Million	354
Zimmer Biomet Holdings Inc	44,758.82	$ 760.900 Million	17,000
Steris Plc	43,187.19	$ 785.100 Million	18,179
Beone Medicines Ltd	42,751.67	$ 513.020 Million	12,000
Pacific Health Care Organization Inc	41,568.03	$ 1.289 Million	31
Escalon Medical Corp	40,327.50	$ 1.613 Million	40
Amphastar Pharmaceuticals Inc	40,095.65	$ 79.229 Million	1,976

Date modified: 2026-06-22T14:32:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.